MX2023004480A - Compuestos anticancerigenos selectivos para canceres er-positivos. - Google Patents

Compuestos anticancerigenos selectivos para canceres er-positivos.

Info

Publication number
MX2023004480A
MX2023004480A MX2023004480A MX2023004480A MX2023004480A MX 2023004480 A MX2023004480 A MX 2023004480A MX 2023004480 A MX2023004480 A MX 2023004480A MX 2023004480 A MX2023004480 A MX 2023004480A MX 2023004480 A MX2023004480 A MX 2023004480A
Authority
MX
Mexico
Prior art keywords
cancer
small molecule
cancer cells
biomodulators
positive cancers
Prior art date
Application number
MX2023004480A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Boudreau
Paul J Hergenrother
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2023004480A publication Critical patent/MX2023004480A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023004480A 2020-10-23 2021-10-21 Compuestos anticancerigenos selectivos para canceres er-positivos. MX2023004480A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063104933P 2020-10-23 2020-10-23
PCT/US2021/056003 WO2022087234A1 (en) 2020-10-23 2021-10-21 Anticancer compounds selective for er-positive cancers

Publications (1)

Publication Number Publication Date
MX2023004480A true MX2023004480A (es) 2023-05-04

Family

ID=81290080

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004480A MX2023004480A (es) 2020-10-23 2021-10-21 Compuestos anticancerigenos selectivos para canceres er-positivos.

Country Status (9)

Country Link
US (1) US12655104B2 (enExample)
EP (1) EP4232038A4 (enExample)
JP (1) JP2023546584A (enExample)
CN (1) CN116723841A (enExample)
AU (2) AU2021366688B2 (enExample)
CA (1) CA3196210A1 (enExample)
IL (1) IL302154A (enExample)
MX (1) MX2023004480A (enExample)
WO (1) WO2022087234A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120981469A (zh) * 2023-02-23 2025-11-18 晨晖生物科技(香港)有限公司 含硼化合物及其治疗用途
WO2026039467A1 (en) * 2024-08-12 2026-02-19 The Board Of Trustees Of The University Of Illinois Hydroxyphenyl-indoline-2-one cancer therapeutics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2855406A (en) 1955-05-07 1958-10-07 Dann Otto Preparation of benzopyrans and benzofurans
US3773759A (en) 1972-08-21 1973-11-20 Searle & Co 1-arylideneamino-4-(2-oxo-3-phenyl-3-benzofuryl)piperazines
FR2810320B1 (fr) 2000-06-19 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
CA2684552A1 (en) * 2007-04-24 2008-10-30 Topotarget A/S Substituted 3-(4-hydroxyphenyl)-indolin-2-one compounds
EA027139B1 (ru) 2013-04-26 2017-06-30 Бейджин, Лтд. Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
CN108440378B (zh) 2018-03-27 2021-03-12 宁波大学 一种室温下碘-双氧水促进的3-氨基-2-吲哚酮衍生物的制备方法
EP3817741A4 (en) * 2018-07-03 2022-07-06 The Board of Trustees of the University of Illinois ACTIVATORS OF THE UNFOLDING PROTEIN RESPONSE

Also Published As

Publication number Publication date
AU2021366688A9 (en) 2024-06-20
US12655104B2 (en) 2026-06-16
EP4232038A4 (en) 2024-04-10
IL302154A (en) 2023-06-01
AU2021366688A1 (en) 2023-05-25
JP2023546584A (ja) 2023-11-06
EP4232038A1 (en) 2023-08-30
AU2026204244A1 (en) 2026-06-18
CA3196210A1 (en) 2022-04-28
WO2022087234A1 (en) 2022-04-28
US20230391721A1 (en) 2023-12-07
CN116723841A (zh) 2023-09-08
AU2021366688B2 (en) 2026-03-05

Similar Documents

Publication Publication Date Title
ZA202501583B (en) Compounds and methods for the targeted degradation of androgen receptor
CR20210060A (es) Activadores de la respuesta a proteínas desplegadas
AR110728A1 (es) Terapia combinada para el tratamiento del cáncer
ZA201904652B (en) Combinations of cabozantinib and atezolizumab to treat cancer
ZA201907225B (en) Treatment of her2 positive cancers
MX2019014021A (es) Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
AU2016256469A8 (en) Methods for treating cancer
SA521430960B1 (ar) NF-κB مثبطات جزيئية صغيرة لكيناز تحفيز
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
MX2024003797A (es) Conjugados de anticuerpos b7-h4 y farmacos para el tratamiento del cancer.
PH12013502494A1 (en) Neutralizing prolactin receptor antibody mat3 and its therapeutic use
MX2020004960A (es) Asociacion de activos para tratar el cancer de prostata.
MX2024007260A (es) Uso de terapia de combinacion para tratar el cancer.
MX2022000853A (es) Anticuerpos anti-liv1 humanizados para el tratamiento de cancer.
MX2025002424A (es) Combinacion de dcc-3116 e inhibidores de la via mapkap para su uso en el tratamiento del cancer
WO2014145817A3 (en) Novel therapeutic target for the treatment of cancers and related therapies and methods
MX2019014298A (es) Formas de dosificacion liquida para tratar el cancer.
PH12021550376A1 (en) Combination therapy
AU2018244925A1 (en) Compositions for the treatment of drug-resistant tumors and methods of use thereof
WO2019190927A3 (en) Splice-switching oligonucleotides and methods of use
Liu et al. Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer
WO2019006002A8 (en) Methods of treating cancer with small molecule nf-kb inhibitors
Laliscia et al. Radiotherapy as definitive treatment of patients with primary vulvar carcinoma unfit for surgery and with recurrent vulvar carcinoma after primary radical surgery: results of a retrospective single-center study
Ritter Commentary on “Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911).” Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups. Department of Radiation Oncology, Centre Hospitalier Universitaire A Michallon, Grenoble, France.: Lancet 2012; 380 (9858): 2018–27